Lv74
3920 积分 2022-06-30 加入
中国乳腺导管原位癌病理诊断共识（2022版）
1个月前
已完结
中国乳腺导管原位癌病理诊断共识（2022版）
1个月前
已关闭
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
2个月前
已完结
Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
11个月前
已完结
Developing therapies for triple-negative breast cancer subtypes
1年前
已完结
Trastuzumab Deruxtecan in Previously Treated Patients With HER2-Positive Metastatic Breast Cancer: Updated Survival Results From a Phase 2 Trial (DESTINY-Breast01)
1年前
已完结
Expression of concern-Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
1年前
已完结
Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
1年前
已完结
Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study
1年前
已完结
皖公网安备34019202002308
